OrbiMed’s Procept Biorobotics PRCT Stock Holding History

OrbiMed’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-135,000	Closed	-$5.15M	–	174
2021 Q3	$5.15M	Buy	+135,000	New	+$5.18M	0.06%	152

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed's PRCT Position: Q4 2021 in Review

OrbiMed sold out of Procept Biorobotics (PRCT) in Q4 2021, closing a stake of 135,000 shares — an estimated $5.15M sold.

OrbiMed first reported a position in PRCT in Q3 2021 and held it in 1 quarter. The position peaked at $5.15M in Q3 2021. 60 funds tracked by Wall St. Rank hold PRCT as of Q4 2021.

OrbiMed reported no remaining Procept Biorobotics position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 135,000 Procept Biorobotics shares in Q4 2021, an estimated $5.15M.
OrbiMed first reported a position in Procept Biorobotics in Q3 2021 and held it in 1 quarter.
OrbiMed's Procept Biorobotics position peaked at $5.15M in Q3 2021.
60 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.